Drug-drug Interactions Studies of VC005 Tablets in Healthy Adult Subjects
Condition(s) studied
Investigational drug(s) / intervention(s)
VC005 and verapamil: A single dose of VC005 was administered in the period 1. and a single dose of VC005 and verapamil coadministration in the period 2.
VC005 and probenecid: A single dose of VC005 was administered in the period 1. and a single dose of VC005 and probenecid coadministration in the period 2.
VC005 and metformin: A single dose of metformin was administered in the period 1. and a single dose of metformin and VC005 coadministration in the period 2
Study summary
This study includes three groups of Drug-Drug Interaction( DDI ) studies:
1. To evaluate the effect of verapamil on the pharmacokinetics of a single oral dose of VC005 in healthy subjects;
2. To evaluate the effect of probenecid on the pharmacokinetics of a single oral dose of VC005 in healthy subjects;
3. To evaluate the effect of VC005 on the pharmacokinetics of a single oral dose of metformin tablets in healthy subjects.
Eligibility
Primary outcome measure(s)
- Maximum Observed Plasma Concentration (Cmax) — Day1-Day12
- Area Under the Curve From Time Zero to Last Quantifiable Concentration(AUC) — Day1-Day12
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Zhongda Hospital,Affiliated to Southeast University | Nanjing | Jiangsu |
More Jiangsu vcare pharmaceutical technology co., LTD trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07796191 on ClinicalTrials.gov ↗ ← All trials in China